Lini Pandite

9.7k total citations · 2 hit papers
76 papers, 6.0k citations indexed

About

Lini Pandite is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lini Pandite has authored 76 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 39 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in Lini Pandite's work include Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (20 papers) and Renal and related cancers (16 papers). Lini Pandite is often cited by papers focused on Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (20 papers) and Renal and related cancers (16 papers). Lini Pandite collaborates with scholars based in United States, United Kingdom and France. Lini Pandite's co-authors include Lauren McCann, Ian D. Davis, Cora N. Sternberg, Juan José Zarbá, Cezary Szczylik, Chen Mei, Carlos H. Barrios, Pamela Salman, Jozef Mardiak and John Wagstaff and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lini Pandite

76 papers receiving 5.9k citations

Hit Papers

Pazopanib in Locally Advanced or Metastatic Renal Cell Ca... 2009 2026 2014 2020 2010 2009 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
    2010 1.9k citations Cora N. Sternberg, Ian D. Davis et al. Journal of Clinical Oncology profile →
  2. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
    2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lini Pandite United States 31 3.8k 3.0k 2.8k 1.6k 608 76 6.0k
Apurva A. Desai United States 21 4.0k 1.1× 3.9k 1.3× 2.5k 0.9× 2.2k 1.4× 505 0.8× 36 6.8k
Samuel E. DePrimo United States 28 2.5k 0.7× 2.7k 0.9× 2.2k 0.8× 1.3k 0.8× 496 0.8× 40 5.3k
Paul Bycott United States 24 4.5k 1.2× 3.7k 1.3× 2.9k 1.1× 2.2k 1.4× 390 0.6× 51 7.1k
Carlo L. Bello United States 27 4.1k 1.1× 3.1k 1.0× 3.1k 1.1× 1.5k 0.9× 549 0.9× 54 7.5k
Minghua Shan United States 17 4.0k 1.1× 3.3k 1.1× 2.0k 0.7× 2.1k 1.3× 412 0.7× 39 6.0k
Isan Chen United States 16 7.0k 1.9× 4.8k 1.6× 3.6k 1.3× 3.1k 1.9× 437 0.7× 41 9.1k
Michael Siebels Germany 22 3.4k 0.9× 2.7k 0.9× 1.6k 0.6× 1.6k 1.0× 318 0.5× 65 5.2k
E Solska United States 4 3.9k 1.0× 3.3k 1.1× 1.9k 0.7× 2.1k 1.3× 373 0.6× 7 5.5k
Jean-­Marc Ferrero France 41 4.0k 1.1× 1.8k 0.6× 6.4k 2.3× 3.0k 1.9× 600 1.0× 207 9.6k
Rogério Lilenbaum United States 33 5.5k 1.4× 2.1k 0.7× 5.6k 2.0× 1.2k 0.8× 421 0.7× 105 8.4k

Countries citing papers authored by Lini Pandite

Since Specialization
Citations

This map shows the geographic impact of Lini Pandite's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lini Pandite with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lini Pandite more than expected).

Fields of papers citing papers by Lini Pandite

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lini Pandite. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lini Pandite. The network helps show where Lini Pandite may publish in the future.

Co-authorship network of co-authors of Lini Pandite

This figure shows the co-authorship network connecting the top 25 collaborators of Lini Pandite. A scholar is included among the top collaborators of Lini Pandite based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lini Pandite. Lini Pandite is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043). Annals of Oncology. 27. vi368–vi368. 2 indexed citations
2.
Xu, Chun‐Fang, Toby Johnson, Xiaojing Wang, et al.. (2015). HLA-B *57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clinical Cancer Research. 22(6). 1371–1377. 70 indexed citations
3.
Xu, Chun‐Fang, Toby Johnson, Jesús García-Donás, et al.. (2015). IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer. 112(7). 1190–1198. 28 indexed citations
4.
Goldstein, David, Jonathan E. Rosenberg, Robert A. Figlin, et al.. (2015). Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. European Journal of Cancer. 53. 96–104. 23 indexed citations
5.
Choueiri, Toni K., David J. Figueroa, André P. Fay, et al.. (2014). Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research. 21(5). 1071–1077. 187 indexed citations
6.
Suttle, A. Benjamin, Howard Ball, Mathiéu Molimard, et al.. (2014). Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer. 111(10). 1909–1916. 147 indexed citations
7.
Choueiri, Toni K., André P. Fay, Robert Gagnon, et al.. (2013). The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(18). 5218–5226. 73 indexed citations
8.
Jonge, Maja J.A. de, Paul Hamberg, Jaap Verweij, et al.. (2012). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs. 31(3). 751–759. 29 indexed citations
9.
Sleijfer, Stefan, Thierry Gorlia, C. B. H. W. Lamers, et al.. (2012). Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. British Journal of Cancer. 107(4). 639–645. 37 indexed citations
10.
Xu, Chun‐Fang, Howard Ball, Nan Bing, et al.. (2011). Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma.. Journal of Clinical Oncology. 29(7_suppl). 303–303. 11 indexed citations
11.
Tran, Hang, Amelia Rodríguez Martín, Amado J. Zurita, et al.. (2011). Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).. Journal of Clinical Oncology. 29(7_suppl). 334–334. 8 indexed citations
12.
Sternberg, Cora N., Ian D. Davis, Jozef Mardiak, et al.. (2010). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 28(6). 1061–1068. 1940 indexed citations breakdown →
13.
Xu, Chun‐Fang, Zhengyu Xue, Li Huang, et al.. (2010). Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British Journal of Cancer. 102(9). 1371–1377. 99 indexed citations
14.
Xu, Chun‐Fang, Vicki Goodman, Zhengyu Xue, et al.. (2010). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of Hepatology. 54(6). 1237–1243. 41 indexed citations
15.
Burris, Howard A., Suzanne F. Jones, Daphne Williams, et al.. (2010). A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Investigational New Drugs. 29(3). 467–472. 52 indexed citations
16.
Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →
17.
Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, et al.. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research. 15(21). 6702–6708. 83 indexed citations
18.
Hutson, Thomas E., Ian D. Davis, Jean‐Pascal Machiels, et al.. (2009). Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 28(3). 475–480. 229 indexed citations
19.
Lee, Jean W., Ronald R. Bowsher, Dean W. Knuth, et al.. (2005). Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report. Pharmaceutical Research. 22(4). 499–511. 125 indexed citations
20.
Schwartz, Garry, Quincy Chu, L. A. Hammond, et al.. (2004). Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3070–3070. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Apurva A. Desai Breakdown of academic impact, for papers by Samuel E. DePrimo Breakdown of academic impact, for papers by Paul Bycott Breakdown of academic impact, for papers by Carlo L. Bello Breakdown of academic impact, for papers by Minghua Shan Breakdown of academic impact, for papers by Isan Chen Breakdown of academic impact, for papers by Michael Siebels Breakdown of academic impact, for papers by E Solska Breakdown of academic impact, for papers by Jean-­Marc Ferrero Breakdown of academic impact, for papers by Rogério Lilenbaum
Rankless by CCL
2026